We are live on
!
Find out more
CM
Caption Management Portfolio holdings
AUM
$17.1B
1-Year Est. Return
70.99%
This Fund
S&P 500
This Quarter
Est. Return
+4.28%
1 Year Est. Return
+70.99%
3 Year Est. Return
+176.06%
5 Year Est. Return
+263.89%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$172M
(+9.5%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
7.83%
Top 10 Holdings %
Top 10 Hldgs %
16.27%
Holding
935
New
395
Increased
92
Reduced
99
Closed
294
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$8.42M |
| 2 |
Marathon Petroleum
MPC
|
+$5.47M |
| 3 |
Liberty Global Class C
LBTYK
|
+$5.39M |
| 4 |
O'Reilly Automotive
ORLY
|
+$5.32M |
| 5 |
Crocs
CROX
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$12.6M |
| 2 |
Tapestry
TPR
|
+$12M |
| 3 |
iShares MSCI Saudi Arabia ETF
KSA
|
+$8.32M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$6.96M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$6.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.95% |
| 2 | Consumer Discretionary | 2.51% |
| 3 | Technology | 1.96% |
| 4 | Energy | 1.43% |
| 5 | Communication Services | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
PUT
Inogen
INGN
$175M
| $2.68M | 0.14% |
+40,200
| New | +$3.06M |
|
202
PUT
Conagra Brands
CAG
$6.94B
| $2.65M | 0.13% |
100,000
-74,200
| -43% | -$2.16M |
|
203
CALL
Arrowhead Research
ARWR
$11.9B
| $2.65M | 0.13% |
+100,000
| New | +$2.19M |
|
204
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
| $2.64M | 0.13% |
+36,400
| New | +$2.79M |
|
|
IMMU
205
CALL
DELISTED
Immunomedics Inc
IMMU
| $2.63M | 0.13% |
190,000
+130,100
| +217% | +$1.96M |
|
206
CALL
Louisiana-Pacific
LPX
$5.06B
| $2.62M | 0.13% |
+100,000
| New | +$2.45M |
|
207
CALL
Ionis Pharmaceuticals
IONS
$8.6B
| $2.57M | 0.13% |
+40,000
| New | +$2.83M |
|
208
CALL
Anika Therapeutics
ANIK
$258M
| $2.56M | 0.13% |
+63,000
| New | +$2.3M |
|
209
CALL
Cencora
COR
$60.6B
| $2.56M | 0.13% |
30,000
| – | – |
|
|
210
PUT
Cencora
COR
$60.6B
| $2.56M | 0.13% |
30,000
| – | – |
|
211
CALL
TIM SA
TIMB
$9.16B
| $2.54M | 0.13% |
+170,000
| New | +$2.47M |
|
212
CALL
Neurocrine Biosciences
NBIX
$16.8B
| $2.53M | 0.13% |
30,000
+7,500
| +33% | +$616K |
|
|
213
PUT
Neurocrine Biosciences
NBIX
$16.8B
| $2.53M | 0.13% |
30,000
-55,000
| -65% | -$4.52M |
|
|
SNBR
214
CALL
DELISTED
Sleep Number
SNBR
| $2.53M | 0.13% |
62,700
-50,300
| -45% | -$1.94M |
|
215
PUT
Occidental Petroleum
OXY
$56.8B
| $2.51M | 0.13% |
+50,000
| New | +$2.81M |
|
|
GRUB
216
DELISTED
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
| $2.5M | 0.13% |
+16,000
| New | +$2.18M |
|
217
CALL
Neogen
NEOG
$2.63B
| $2.48M | 0.13% |
+80,000
| New | +$2.36M |
|
|
CTLT
218
DELISTED
CATALENT, INC.
CTLT
| $2.44M | 0.12% |
+45,000
| New | +$2.06M |
|
|
I
219
CALL
DELISTED
INTELSAT S. A.
I
| $2.43M | 0.12% |
125,000
+80,500
| +181% | +$1.56M |
|
220
PUT
LiveRamp
RAMP
$2.3B
| $2.42M | 0.12% |
+50,000
| New | +$2.71M |
|
221
Ashland
ASH
$3.33B
| $2.4M | 0.12% |
30,000
+21,000
| +233% | +$1.62M |
|
222
CALL
Williams Companies
WMB
$87.5B
| $2.38M | 0.12% |
+85,000
| New | +$2.36M |
|
223
Itron
ITRI
$4.36B
| $2.38M | 0.12% |
+38,000
| New | +$2.11M |
|
224
CALL
Perrigo
PRGO
$1.4B
| $2.36M | 0.12% |
+49,500
| New | +$2.36M |
|
|
225
PUT
Perrigo
PRGO
$1.4B
| $2.36M | 0.12% |
+49,500
| New | +$2.36M |
|
Similar funds
ASRS
PP
VMPIC
BCIM
BBA
FCM
AIMCA
Caption Management's Q2 2019 Portfolio in Review
As of Q2 2019, Caption Management held 935 positions worth $1.99B, up 9.5% from $1.81B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Caption Management deployed $156M of net new capital in Q2 2019, opening 395 new positions and adding to 92 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 78,000 shares worth $7.99M.
By sector, the portfolio is most concentrated in Healthcare at 3% of assets, down from 3.9% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $12.6M trimmed.
- Caption Management's largest Q2 2019 buy was Spark Therapeutics, Inc. Common Stock: 78,000 shares worth $7.99M.
- Caption Management added most to Crocs in Q2 2019, an estimated $5.07M increase.
- Caption Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $12.6M.
- Caption Management fully exited iShares MSCI Saudi Arabia ETF in Q2 2019, selling an estimated $8.32M.
- Caption Management's ten largest holdings make up 16% of its $1.99B portfolio in Q2 2019.
- Caption Management opened 395 new positions and closed 294 in Q2 2019.
- Caption Management's portfolio value rose 9.5% quarter-over-quarter to $1.99B.
Based on Caption Management's 13F filing for Q2 2019, filed 13 Aug 2019.